Form 4: ProKidney Director Brian Pereira Receives Stock Options

Director Brian J.G. Pereira was granted 135,000 stock options in ProKidney Corp. as part of the company's non-employee director compensation policy.

Summary

• Director Brian J.G. Pereira received a grant of 135,000 stock options on May 28, 2026.
• The options have an exercise price of $1.81 per share.
• The options are set to expire on May 28, 2036.
• Vesting occurs on the earlier of the one-year anniversary of the grant or the date of the next annual general shareholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying Class A Common Stock.
• The exercise price of $1.81 may be subject to market fluctuations.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant or the date of the company's next annual general shareholder meeting.

Management Comments

• The grant is consistent with the Issuer's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to drive long-term company performance.

Comparison to Industry Standards

• The use of time-based vesting (one year or next annual meeting) is standard practice for non-employee director compensation in mid-cap biotech firms.
• The grant size is typical for board-level equity compensation packages in the clinical-stage pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on the earlier of May 28, 2027, or the next annual general shareholder meeting.

Key Dates

Keywords

ProKidney, PROK, Director Compensation, Stock Options, Insider Transaction, Form 4